These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17041633)

  • 21. Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure.
    Brumme ZL; Chopera DR; Brockman MA
    Curr Opin Virol; 2012 Oct; 2(5):599-605. PubMed ID: 22939190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
    Yang OO
    AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
    [No Abstract]   [Full Text] [Related]  

  • 23. Diversity considerations in HIV-1 vaccine selection.
    Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
    Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 25. Potential vaccination strategy focuses on reactivating latent HIV.
    Patience J
    Expert Rev Anti Infect Ther; 2012 May; 10(5):526. PubMed ID: 22702324
    [No Abstract]   [Full Text] [Related]  

  • 26. Viral sequence diversity: challenges for AIDS vaccine designs.
    McBurney SP; Ross TM
    Expert Rev Vaccines; 2008 Nov; 7(9):1405-17. PubMed ID: 18980542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals.
    Kulkarni PS; Butera ST; Duerr AC
    AIDS Rev; 2003; 5(2):87-103. PubMed ID: 12876898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point.
    Gupta SB; Jacobson LP; Margolick JB; Rinaldo CR; Phair JP; Jamieson BD; Mehrotra DV; Robertson MN; Straus WL
    J Infect Dis; 2007 Feb; 195(4):546-50. PubMed ID: 17230414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Support for the RV144 HIV vaccine trial.
    AIDS Vaccine Advocacy Coalition
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
    [No Abstract]   [Full Text] [Related]  

  • 32. Outwitting HIV: Minnesota researchers take on a clever virus.
    Bell H
    Minn Med; 2009 Oct; 92(10):22-6. PubMed ID: 19916268
    [No Abstract]   [Full Text] [Related]  

  • 33. HIV-1 T-cell vaccines: evaluating the next step.
    Pantaleo G
    Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
    [No Abstract]   [Full Text] [Related]  

  • 34. The essential detail: the genetics and genomics of the primate immune response.
    Shen S; Pyo CW; Vu Q; Wang R; Geraghty DE
    ILAR J; 2013; 54(2):181-95. PubMed ID: 24174441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First genome-wide study of infectious disease opens new avenues for HIV treatment: vaccines.
    AIDS Patient Care STDS; 2007 Aug; 21(8):607. PubMed ID: 17902246
    [No Abstract]   [Full Text] [Related]  

  • 36. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of mucosal immunity to HIV-1.
    Jespers V; Harandi AM; Hinkula J; Medaglini D; Le Grand R; Stahl-Hennig C; Bogers W; El Habib R; Wegmann F; Fraser C; Cranage M; Shattock RJ; Spetz AL
    Expert Rev Vaccines; 2010 Apr; 9(4):381-94. PubMed ID: 20370549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1/AIDS vaccine development: are we in the darkness.
    Qiu C; Xu JQ
    Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210
    [No Abstract]   [Full Text] [Related]  

  • 40. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.